Full-Time
Principal – Customer Success
Folia Health
11-50 employees
Collects and analyzes patient-generated health data
Compensation Overview
$125k - $150k/yr
No H1B Sponsorship
Boston, MA, USA
Hybrid
Must be able to commute to downtown Boston weekly; hybrid in-office schedule with Tue/Thu in-office days.
Bachelor's
 Customer Experience & Support (1) |
|---|
Get referred to Folia Health
See people who can refer or advise you
- Bachelor’s degree is required, advanced degree in a relevant field is a bonus
- 6+ years of experience in customer success, account management, or client-facing commercial/scientific roles, ideally within life sciences, pharma, healthcare, or research services
- Demonstrated ability to own sponsor or client relationships and manage the success of multiple projects over time
- Ability to engage credibly with both scientific and commercial stakeholders, and to translate research insights into commercial value
- First principles thinking and a knack for turning insight into action
- Strong communication, relationship-building, and account strategy skills
- Own client relationships across multiple sponsors; serve as the clients’ primary point of contact and the person they always know to come to throughout the entire end-to-end research lifecycle
- Partner closely with the Folia Research team including research scientists and data scientists, in order to ensure sponsors experience Folia’s science with full scientific credibility and clear commercial relevance
- Translate Folia research findings into commercially-usable outputs and lead client-facing deliverable presentations
- Support the Commercial team with renewals and account expansion: map accounts, surface the strongest insights, and hold the relationship connection
Folia Health builds a free mobile platform that helps patients and caregivers track health observations for more than 600 conditions. Users log symptoms, treatments, flare-ups and daily activities in customizable journals, logs, and schedules. The app turns qualitative experiences into longitudinal data called Home-Reported Outcomes (HROs), which are visualized in graphs and reports and can be shared with clinicians to support data-driven care. Folia Health differentiates itself by focusing on patient-generated, longitudinal real-world data and by partnering with life sciences companies to provide anonymized, aggregated data for clinical trial design, endpoint development, and patient-centered drug development. It also runs a Data Dividends program that rewards users with gift cards for consistently tracking and opting to share their anonymized data. The company’s goal is to empower patients and families to improve care and speed patient-focused research through real-world evidence.
Company Size
11-50
Company Stage
Series A
Total Funding
$11M
Headquarters
Cambridge, Massachusetts
Founded
2016
Get referred to Folia Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- October 2025 Series A from S3 Ventures, Crosslink, and Create Health funds expansion.
- August 2026 FSGS PULSE and April 2026 BRAVE-PWS broaden rare-disease study throughput.
- Joining CancerX strengthens distribution with major healthcare stakeholders and accelerates sponsor credibility.
What critics are saying
- Pharma partnerships like argenx and Soleno concentrate revenue; one cancelled study hits 2026 bookings.
- Gift-card Data Dividends and self-tracking rely on user engagement; dropoff ruins longitudinal datasets.
- If sponsors stop funding studies, Folia loses its only monetization engine and product moat.
What makes Folia Health unique
- Folia Health turns caregiver journals into Home-Reported Outcomes, a distinct clinical dataset.
- Its April 2026 argenx CIDP study tracks symptoms between visits, not clinic snapshots.
- The platform spans 600-plus conditions, enabling rare-disease research across repeated use cases.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
401(k) Retirement Plan
Stock Options
Growth & Insights and Company News
6 month growth
↑ 12%1 year growth
↑ 12%2 year growth
↑ 15%Folia Health has launched the FSGS PULSE Study, a remote observational study examining disease burden and treatment impact in people with focal segmental glomerulosclerosis (FSGS), a rare kidney disease. During a six-month period, participants will use Folia's platform to track symptoms and quality-of-life impacts alongside their treatment plans. The resulting dataset will provide researchers with detailed insights into daily experiences with FSGS and treatment outcomes. The platform enables patients to monitor symptoms and share data with their care teams. "People living with rare kidney diseases need more evidence from the real world to understand which therapeutic plan may be best," said Nell Meosky Luo, founder and CEO of Folia Health. Founded in 2016, Boston-based Folia Health specialises in transforming patient experiences into structured data for research and personalised care.
Folia Health has launched an app-based observational study in collaboration with argenx to capture real-world evidence from patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and their caregivers. The initiative represents the first real-world data programme designed to track at-home experiences of individuals living with the condition. The study uses Folia's home-reported outcomes platform, allowing participants to select and monitor symptoms that matter most to them whilst documenting treatment plans over an initial six-month period. The platform tracks symptom severity, treatment utilisation and daily disease management aspects. Boston-based Folia Health, founded in 2016, specialises in transforming patient experiences into structured data insights. The company works across chronic and rare conditions to generate clinical-grade real-world evidence whilst maintaining data privacy and patient autonomy.
Folia Health launches app-based study to unlock novel real-world evidence of symptom burden and unmet need for patients and caregivers in CIDP. April 07, 2026 10:00 ET | Source: Folia Health BOSTON, April 07, 2026 (GLOBE NEWSWIRE) - Folia Health today announced a collaboration with argenx to launch a first-of-its-kind, at-home observational real-world evidence initiative supporting individuals living with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). "Our team at Folia shows up to work every day to translate the lived experience of patients into research-grade data that can be used to inform the therapies..." The study represents the first real-world data program designed to capture the at-home experiences of individuals with CIDP and their caregivers. Designed in partnership with patients and caregivers, the initiative leverages Folia's home-reported outcomes (HROs) platform, enabling participants to select and track the symptoms that matter most to them while documenting their individualized treatment plans. Over time, the platform captures symptom severity, treatment utilization, and other aspects of daily disease management directly from patients over an initial six-month period. "Our team at Folia shows up to work every day to translate the lived experience of patients into research-grade data that can be used to inform the therapies available to help people. With our partners at argenx, we are very motivated to be able to describe the diverse experiences of people living with CIDP, including difficulties with nerve pain and symptom flare ups. We hope that this work will pave the way for care plans that enable people with CIDP and their caregivers to achieve a better quality of life with less interference from their disease." said Nell Meosky Luo, the CEO & Founder of Folia Health. HROs tracked by patients and caregivers provide a continuous view of what happens between clinic visits, overlaying tracked symptoms and treatments with real-world quality-of-life impacts such as the ability to work, engage in everyday activities, and navigate life independently. Through the Folia platform, CIDP patients and caregivers can actively engage with their own study data and gain deeper insights into their symptom burden, treatment effects, and acute health events. The Folia app generates tracking summary reports that let patients easily visualize changes over time, including symptom severity trends, flare frequency, and treatment responses. Calendar filtering tools further enable patients to see when symptoms, flares, and other health events occur, which may help them identify patterns and understand how treatments may influence daily life. The platform can overlay treatment usage with symptom severity, and patients can export visual reports to share meaningful insights with their care teams. About Folia Health: Folia Health is a patient-led health company and the pioneer of home-reported outcomes (HROs), transforming lived health experiences into valuable structured data insights to advance research and personalized care. The company's platform is built on the belief that the knowledge of patients and caregivers is the missing piece to enable precise, individualized care and high-impact research. Through a useful platform, radical transparency, explicit consent protocols, and data dividend payments, Folia bridges the gap between patients, clinicians, and researchers while maintaining the highest standards of data privacy and patient autonomy. Founded in 2016 by family caregivers and based in Boston, Folia works with individuals across chronic and rare conditions to generate clinical-grade real-world evidence. For more information, visit www.foliahealth.com. Folia Health Contact: Matt Berry Director of Marketing [email protected]
Folia Health announced the close of a $10.5 million Series A funding round led by S3 Ventures, with participation from Crosslink Capital and Create Health Ventures. The funding will support Folia's mission to empower patients by transforming their experiences into structured data for research and personalized care. Folia's platform allows patients to track and share health data with control and transparency, contributing to research and AI-driven healthcare insights.
Folia Health secures $10.5M in funding to transform healthcare and research with patient-reported information.